#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Materials and Methods
1-1	0-2	2.	substance[1]	new[1]	_	_
1-2	3-12	Materials	substance[1]	new[1]	_	_
1-3	13-16	and	_	_	_	_
1-4	17-24	Methods	abstract	new	coref	10-108

#Text=This study was designed and developed according to the preferred reporting items for systematic reviews and meta-analysis ( PRISMA ) guidelines , an evidence-based set of minimum items for assessing the benefits and harms of a given healthcare intervention .
2-1	25-29	This	abstract[3]	new[3]	coref	16-16[125_3]
2-2	30-35	study	abstract[3]	new[3]	_	_
2-3	36-39	was	_	_	_	_
2-4	40-48	designed	_	_	_	_
2-5	49-52	and	_	_	_	_
2-6	53-62	developed	_	_	_	_
2-7	63-72	according	_	_	_	_
2-8	73-75	to	_	_	_	_
2-9	76-79	the	object[5]	new[5]	_	_
2-10	80-89	preferred	object[5]	new[5]	_	_
2-11	90-99	reporting	abstract|object[5]	new|new[5]	_	_
2-12	100-105	items	object[5]	new[5]	_	_
2-13	106-109	for	object[5]	new[5]	_	_
2-14	110-120	systematic	object[5]|abstract[6]	new[5]|new[6]	_	_
2-15	121-128	reviews	object[5]|abstract[6]	new[5]|new[6]	_	_
2-16	129-132	and	object[5]	new[5]	_	_
2-17	133-146	meta-analysis	object[5]|abstract	new[5]|new	appos	2-19
2-18	147-148	(	object[5]	new[5]	_	_
2-19	149-155	PRISMA	object[5]|abstract	new[5]|giv	_	_
2-20	156-157	)	object[5]	new[5]	_	_
2-21	158-168	guidelines	object[5]|abstract	new[5]|new	coref	20-15[156_0]
2-22	169-170	,	object[5]	new[5]	_	_
2-23	171-173	an	object[5]|abstract[10]	new[5]|new[10]	_	_
2-24	174-188	evidence-based	object[5]|abstract[10]	new[5]|new[10]	_	_
2-25	189-192	set	object[5]|abstract[10]	new[5]|new[10]	_	_
2-26	193-195	of	object[5]|abstract[10]	new[5]|new[10]	_	_
2-27	196-203	minimum	object[5]|abstract[10]|object[11]	new[5]|new[10]|new[11]	_	_
2-28	204-209	items	object[5]|abstract[10]|object[11]	new[5]|new[10]|new[11]	_	_
2-29	210-213	for	_	_	_	_
2-30	214-223	assessing	_	_	_	_
2-31	224-227	the	abstract[12]	new[12]	_	_
2-32	228-236	benefits	abstract[12]	new[12]	_	_
2-33	237-240	and	_	_	_	_
2-34	241-246	harms	abstract[13]	new[13]	_	_
2-35	247-249	of	abstract[13]	new[13]	_	_
2-36	250-251	a	abstract[13]|event[15]	new[13]|new[15]	coref	10-120[85_15]
2-37	252-257	given	abstract[13]|event[15]	new[13]|new[15]	_	_
2-38	258-268	healthcare	abstract[13]|organization|event[15]	new[13]|new|new[15]	_	_
2-39	269-281	intervention	abstract[13]|event[15]	new[13]|new[15]	_	_
2-40	282-283	.	_	_	_	_

#Text=2.1 .
3-1	284-287	2.1	abstract	new	_	_
3-2	288-289	.	_	_	_	_

#Text=Literature Search
4-1	290-300	Literature	abstract|abstract[18]	new|new[18]	coref|coref	5-3[20_0]|14-7[103_18]
4-2	301-307	Search	abstract[18]	new[18]	_	_

#Text=We searched the literature in various electronic bibliographic databases ( PubMed/Medline , Embase , EBSCO , Cochrane databases , Lilacs , and Dialnet ) for all entries up until 30 March 2019 , without applying any publication age limitations .
5-1	308-310	We	person	acc	ana	10-3
5-2	311-319	searched	_	_	_	_
5-3	320-323	the	abstract[20]	giv[20]	coref	14-8[0_20]
5-4	324-334	literature	abstract[20]	giv[20]	_	_
5-5	335-337	in	_	_	_	_
5-6	338-345	various	object[21]	new[21]	coref	5-17[26_21]
5-7	346-356	electronic	object[21]	new[21]	_	_
5-8	357-370	bibliographic	object[21]	new[21]	_	_
5-9	371-380	databases	object[21]	new[21]	_	_
5-10	381-382	(	_	_	_	_
5-11	383-397	PubMed/Medline	organization	new	_	_
5-12	398-399	,	_	_	_	_
5-13	400-406	Embase	organization	new	_	_
5-14	407-408	,	_	_	_	_
5-15	409-414	EBSCO	organization	new	_	_
5-16	415-416	,	_	_	_	_
5-17	417-425	Cochrane	organization|object[26]	new|giv[26]	coref|coref	7-7[42_26]|20-16
5-18	426-435	databases	object[26]	giv[26]	_	_
5-19	436-437	,	_	_	_	_
5-20	438-444	Lilacs	organization	new	_	_
5-21	445-446	,	_	_	_	_
5-22	447-450	and	_	_	_	_
5-23	451-458	Dialnet	organization	new	_	_
5-24	459-460	)	_	_	_	_
5-25	461-464	for	_	_	_	_
5-26	465-468	all	place[29]	new[29]	_	_
5-27	469-476	entries	place[29]	new[29]	_	_
5-28	477-479	up	place[29]	new[29]	_	_
5-29	480-485	until	place[29]	new[29]	_	_
5-30	486-488	30	place[29]|time[30]	new[29]|new[30]	_	_
5-31	489-494	March	place[29]|time[30]|time[31]	new[29]|new[30]|new[31]	_	_
5-32	495-499	2019	place[29]|time[30]|time[31]|time	new[29]|new[30]|new[31]|new	_	_
5-33	500-501	,	_	_	_	_
5-34	502-509	without	_	_	_	_
5-35	510-518	applying	_	_	_	_
5-36	519-522	any	abstract[35]	new[35]	_	_
5-37	523-534	publication	abstract|abstract[35]	new|new[35]	_	_
5-38	535-538	age	abstract|abstract[35]	new|new[35]	coref	16-25[128_0]
5-39	539-550	limitations	abstract[35]	new[35]	_	_
5-40	551-552	.	_	_	_	_

#Text=The reference lists of all the relevant articles were manually cross-referenced in order to identify any additional articles .
6-1	553-556	The	object[37]	new[37]	_	_
6-2	557-566	reference	abstract|object[37]	new|new[37]	_	_
6-3	567-572	lists	object[37]	new[37]	_	_
6-4	573-575	of	object[37]	new[37]	_	_
6-5	576-579	all	object[37]|abstract[38]	new[37]|new[38]	coref	6-16[39_38]
6-6	580-583	the	object[37]|abstract[38]	new[37]|new[38]	_	_
6-7	584-592	relevant	object[37]|abstract[38]	new[37]|new[38]	_	_
6-8	593-601	articles	object[37]|abstract[38]	new[37]|new[38]	_	_
6-9	602-606	were	_	_	_	_
6-10	607-615	manually	_	_	_	_
6-11	616-632	cross-referenced	_	_	_	_
6-12	633-635	in	_	_	_	_
6-13	636-641	order	_	_	_	_
6-14	642-644	to	_	_	_	_
6-15	645-653	identify	_	_	_	_
6-16	654-657	any	abstract[39]	giv[39]	coref	15-24[114_39]
6-17	658-668	additional	abstract[39]	giv[39]	_	_
6-18	669-677	articles	abstract[39]	giv[39]	_	_
6-19	678-679	.	_	_	_	_

#Text=The primary search terms used for all six databases were ‘ leucine ’ and ‘ sarcopenia ’ , as well as one of the following terms : ‘ older ’ , ‘ elderly ’ , ‘ disease ’ or ‘ trial ’ .
7-1	680-683	The	abstract[41]	new[41]	coref	7-24[46_41]
7-2	684-691	primary	abstract[41]	new[41]	_	_
7-3	692-698	search	event|abstract[41]	new|new[41]	_	_
7-4	699-704	terms	abstract[41]	new[41]	_	_
7-5	705-709	used	_	_	_	_
7-6	710-713	for	_	_	_	_
7-7	714-717	all	object[42]	giv[42]	_	_
7-8	718-721	six	object[42]	giv[42]	_	_
7-9	722-731	databases	object[42]	giv[42]	_	_
7-10	732-736	were	_	_	_	_
7-11	737-738	‘	abstract[43]	new[43]	coref	10-117[0_43]
7-12	739-746	leucine	abstract[43]	new[43]	_	_
7-13	747-748	’	abstract[43]	new[43]	_	_
7-14	749-752	and	abstract[43]	new[43]	_	_
7-15	753-754	‘	abstract[43]|abstract[44]	new[43]|new[44]	coref	10-80[0_44]
7-16	755-765	sarcopenia	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-17	766-767	’	abstract[43]|abstract[44]	new[43]|new[44]	_	_
7-18	768-769	,	abstract[43]	new[43]	_	_
7-19	770-772	as	abstract[43]	new[43]	_	_
7-20	773-777	well	abstract[43]	new[43]	_	_
7-21	778-780	as	abstract[43]	new[43]	_	_
7-22	781-784	one	abstract[43]|abstract[45]	new[43]|new[45]	_	_
7-23	785-787	of	abstract[43]|abstract[45]	new[43]|new[45]	_	_
7-24	788-791	the	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|giv[46]	appos	7-32[48_46]
7-25	792-801	following	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|giv[46]	_	_
7-26	802-807	terms	abstract[43]|abstract[45]|abstract[46]	new[43]|new[45]|giv[46]	_	_
7-27	808-809	:	_	_	_	_
7-28	810-811	‘	_	_	_	_
7-29	812-817	older	_	_	_	_
7-30	818-819	’	_	_	_	_
7-31	820-821	,	_	_	_	_
7-32	822-823	‘	abstract[48]	giv[48]	_	_
7-33	824-831	elderly	abstract[48]	giv[48]	_	_
7-34	832-833	’	abstract[48]	giv[48]	_	_
7-35	834-835	,	abstract[48]	giv[48]	_	_
7-36	836-837	‘	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
7-37	838-845	disease	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
7-38	846-847	’	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
7-39	848-850	or	abstract[48]	giv[48]	_	_
7-40	851-852	‘	abstract[48]	giv[48]	_	_
7-41	853-858	trial	abstract[48]	giv[48]	_	_
7-42	859-860	’	abstract[48]	giv[48]	_	_
7-43	861-862	.	_	_	_	_

#Text=2.2 .
8-1	863-866	2.2	abstract	new	_	_
8-2	867-868	.	_	_	_	_

#Text=Inclusion and Exclusion Criteria
9-1	869-878	Inclusion	person|abstract[51]	new|new[51]	coref|coref	10-11|15-34[118_51]
9-2	879-882	and	abstract[51]	new[51]	_	_
9-3	883-892	Exclusion	abstract[51]|abstract|abstract[53]	new[51]|new|new[53]	coref	10-9[59_53]
9-4	893-901	Criteria	abstract[51]|abstract[53]	new[51]|new[53]	_	_

#Text=To answer our research questions , we applied the following inclusion criteria to each of the considered manuscripts : ( 1 ) It was acknowledged as an original article ; we included experimental studies ( randomised and placebo-controlled trials ) and observational studies ( cohort , cross-sectional , and case-control studies ) ; ( 2 ) it was a full text published either in English , Portuguese , or Spanish ; ( 3 ) at least one of the sarcopenia criteria was measured : Muscular mass and/or muscular strength and/or physical performance ; ( 4 ) a description of how sarcopenia was evaluated was defined in the methods section ; ( 5 ) the concentration of leucine used in the intervention was specified or could be calculated .
10-1	902-904	To	_	_	_	_
10-2	905-911	answer	_	_	_	_
10-3	912-915	our	person|abstract[56]	giv|new[56]	ana	10-7
10-4	916-924	research	abstract|abstract[56]	new|new[56]	_	_
10-5	925-934	questions	abstract[56]	new[56]	_	_
10-6	935-936	,	_	_	_	_
10-7	937-939	we	person	giv	ana	10-31
10-8	940-947	applied	_	_	_	_
10-9	948-951	the	abstract[59]	giv[59]	coref	10-79[75_59]
10-10	952-961	following	abstract[59]	giv[59]	_	_
10-11	962-971	inclusion	person|abstract[59]	giv|giv[59]	ana	10-23
10-12	972-980	criteria	abstract[59]	giv[59]	_	_
10-13	981-983	to	abstract[59]	giv[59]	_	_
10-14	984-988	each	abstract[59]	giv[59]	_	_
10-15	989-991	of	abstract[59]	giv[59]	_	_
10-16	992-995	the	abstract[59]|object[60]	giv[59]|new[60]	coref	14-3[101_60]
10-17	996-1006	considered	abstract[59]|object[60]	giv[59]|new[60]	_	_
10-18	1007-1018	manuscripts	abstract[59]|object[60]	giv[59]|new[60]	_	_
10-19	1019-1020	:	_	_	_	_
10-20	1021-1022	(	_	_	_	_
10-21	1023-1024	1	_	_	_	_
10-22	1025-1026	)	_	_	_	_
10-23	1027-1029	It	person	giv	ana	10-57
10-24	1030-1033	was	_	_	_	_
10-25	1034-1046	acknowledged	_	_	_	_
10-26	1047-1049	as	_	_	_	_
10-27	1050-1052	an	_	_	_	_
10-28	1053-1061	original	_	_	_	_
10-29	1062-1069	article	_	_	_	_
10-30	1070-1071	;	_	_	_	_
10-31	1072-1074	we	person	giv	ana	15-34
10-32	1075-1083	included	_	_	_	_
10-33	1084-1096	experimental	event[63]	new[63]	_	_
10-34	1097-1104	studies	event[63]	new[63]	_	_
10-35	1105-1106	(	_	_	_	_
10-36	1107-1117	randomised	_	_	_	_
10-37	1118-1121	and	_	_	_	_
10-38	1122-1140	placebo-controlled	_	_	_	_
10-39	1141-1147	trials	abstract	new	_	_
10-40	1148-1149	)	_	_	_	_
10-41	1150-1153	and	_	_	_	_
10-42	1154-1167	observational	event[65]	new[65]	coref	10-50[67_65]
10-43	1168-1175	studies	event[65]	new[65]	_	_
10-44	1176-1177	(	_	_	_	_
10-45	1178-1184	cohort	abstract	new	_	_
10-46	1185-1186	,	_	_	_	_
10-47	1187-1202	cross-sectional	_	_	_	_
10-48	1203-1204	,	_	_	_	_
10-49	1205-1208	and	_	_	_	_
10-50	1209-1221	case-control	event[67]	giv[67]	coref	11-1[0_67]
10-51	1222-1229	studies	event[67]	giv[67]	_	_
10-52	1230-1231	)	event[67]	giv[67]	_	_
10-53	1232-1233	;	event[67]	giv[67]	_	_
10-54	1234-1235	(	event[67]	giv[67]	_	_
10-55	1236-1237	2	event[67]	giv[67]	_	_
10-56	1238-1239	)	event[67]	giv[67]	_	_
10-57	1240-1242	it	person	giv	coref	10-59[69_0]
10-58	1243-1246	was	_	_	_	_
10-59	1247-1248	a	person[69]	giv[69]	coref	15-34[117_69]
10-60	1249-1253	full	person[69]	giv[69]	_	_
10-61	1254-1258	text	person[69]	giv[69]	_	_
10-62	1259-1268	published	_	_	_	_
10-63	1269-1275	either	abstract[70]	new[70]	_	_
10-64	1276-1278	in	abstract[70]	new[70]	_	_
10-65	1279-1286	English	abstract[70]	new[70]	_	_
10-66	1287-1288	,	_	_	_	_
10-67	1289-1299	Portuguese	abstract	new	_	_
10-68	1300-1301	,	_	_	_	_
10-69	1302-1304	or	_	_	_	_
10-70	1305-1312	Spanish	abstract[72]	new[72]	_	_
10-71	1313-1314	;	abstract[72]	new[72]	_	_
10-72	1315-1316	(	abstract[72]	new[72]	_	_
10-73	1317-1318	3	abstract[72]	new[72]	_	_
10-74	1319-1320	)	abstract[72]	new[72]	_	_
10-75	1321-1323	at	abstract[73]	new[73]	_	_
10-76	1324-1329	least	abstract[73]	new[73]	_	_
10-77	1330-1333	one	abstract[73]	new[73]	_	_
10-78	1334-1336	of	abstract[73]	new[73]	_	_
10-79	1337-1340	the	abstract[73]|abstract[75]	new[73]|giv[75]	coref	15-37[120_75]
10-80	1341-1351	sarcopenia	abstract[73]|abstract|abstract[75]	new[73]|giv|giv[75]	coref	10-101
10-81	1352-1360	criteria	abstract[73]|abstract[75]	new[73]|giv[75]	_	_
10-82	1361-1364	was	_	_	_	_
10-83	1365-1373	measured	_	_	_	_
10-84	1374-1375	:	_	_	_	_
10-85	1376-1384	Muscular	abstract[76]	new[76]	_	_
10-86	1385-1389	mass	abstract[76]	new[76]	_	_
10-87	1390-1396	and/or	_	_	_	_
10-88	1397-1405	muscular	abstract[77]	new[77]	_	_
10-89	1406-1414	strength	abstract[77]	new[77]	_	_
10-90	1415-1421	and/or	abstract[77]	new[77]	_	_
10-91	1422-1430	physical	abstract[77]|abstract[78]	new[77]|new[78]	coref	20-38[0_78]
10-92	1431-1442	performance	abstract[77]|abstract[78]	new[77]|new[78]	_	_
10-93	1443-1444	;	_	_	_	_
10-94	1445-1446	(	_	_	_	_
10-95	1447-1448	4	_	_	_	_
10-96	1449-1450	)	_	_	_	_
10-97	1451-1452	a	abstract[79]	new[79]	_	_
10-98	1453-1464	description	abstract[79]	new[79]	_	_
10-99	1465-1467	of	abstract[79]	new[79]	_	_
10-100	1468-1471	how	abstract[79]	new[79]	_	_
10-101	1472-1482	sarcopenia	abstract	giv	coref	16-50
10-102	1483-1486	was	_	_	_	_
10-103	1487-1496	evaluated	_	_	_	_
10-104	1497-1500	was	_	_	_	_
10-105	1501-1508	defined	_	_	_	_
10-106	1509-1511	in	_	_	_	_
10-107	1512-1515	the	abstract[82]	new[82]	_	_
10-108	1516-1523	methods	abstract|abstract[82]	giv|new[82]	coref	16-50[138_0]
10-109	1524-1531	section	abstract[82]	new[82]	_	_
10-110	1532-1533	;	_	_	_	_
10-111	1534-1535	(	_	_	_	_
10-112	1536-1537	5	_	_	_	_
10-113	1538-1539	)	_	_	_	_
10-114	1540-1543	the	quantity[83]	new[83]	_	_
10-115	1544-1557	concentration	quantity[83]	new[83]	_	_
10-116	1558-1560	of	quantity[83]	new[83]	_	_
10-117	1561-1568	leucine	quantity[83]|abstract	new[83]|giv	coref	16-42
10-118	1569-1573	used	_	_	_	_
10-119	1574-1576	in	_	_	_	_
10-120	1577-1580	the	event[85]	giv[85]	_	_
10-121	1581-1593	intervention	event[85]	giv[85]	_	_
10-122	1594-1597	was	_	_	_	_
10-123	1598-1607	specified	_	_	_	_
10-124	1608-1610	or	_	_	_	_
10-125	1611-1616	could	_	_	_	_
10-126	1617-1619	be	_	_	_	_
10-127	1620-1630	calculated	_	_	_	_
10-128	1631-1632	.	_	_	_	_

#Text=Studies performed in animals , case-report studies , letters to the Editor , abstracts from conferences , books , PhD theses were excluded .
11-1	1633-1640	Studies	event	giv	coref	11-6[88_0]
11-2	1641-1650	performed	_	_	_	_
11-3	1651-1653	in	_	_	_	_
11-4	1654-1661	animals	animal	new	_	_
11-5	1662-1663	,	_	_	_	_
11-6	1664-1675	case-report	event[88]	giv[88]	coref	15-6[0_88]
11-7	1676-1683	studies	event[88]	giv[88]	_	_
11-8	1684-1685	,	_	_	_	_
11-9	1686-1693	letters	abstract[89]	new[89]	_	_
11-10	1694-1696	to	abstract[89]	new[89]	_	_
11-11	1697-1700	the	abstract[89]|person[90]	new[89]|new[90]	_	_
11-12	1701-1707	Editor	abstract[89]|person[90]	new[89]|new[90]	_	_
11-13	1708-1709	,	abstract[89]	new[89]	_	_
11-14	1710-1719	abstracts	abstract[89]|abstract[91]	new[89]|new[91]	coref	15-22[113_91]
11-15	1720-1724	from	abstract[89]|abstract[91]	new[89]|new[91]	_	_
11-16	1725-1736	conferences	abstract[89]|abstract[91]|event	new[89]|new[91]|new	_	_
11-17	1737-1738	,	abstract[89]|abstract[91]	new[89]|new[91]	_	_
11-18	1739-1744	books	abstract[89]|abstract[91]|object	new[89]|new[91]|new	_	_
11-19	1745-1746	,	abstract[89]|abstract[91]	new[89]|new[91]	_	_
11-20	1747-1750	PhD	abstract[89]|abstract[91]|abstract|object[95]	new[89]|new[91]|new|new[95]	_	_
11-21	1751-1757	theses	abstract[89]|abstract[91]|object[95]	new[89]|new[91]|new[95]	_	_
11-22	1758-1762	were	_	_	_	_
11-23	1763-1771	excluded	_	_	_	_
11-24	1772-1773	.	_	_	_	_

#Text=2.3 .
12-1	1774-1777	2.3	abstract	new	_	_
12-2	1778-1779	.	_	_	_	_

#Text=Data Collection and Analysis
13-1	1780-1784	Data	abstract|abstract[98]	new|new[98]	_	_
13-2	1785-1795	Collection	abstract[98]	new[98]	_	_
13-3	1796-1799	and	_	_	_	_
13-4	1800-1808	Analysis	abstract	new	_	_

#Text=Details of the manuscripts identified in the literature search were uploaded into a web-based system , which was used to manage the screening process and remove any duplicate citations .
14-1	1809-1816	Details	object[100]	new[100]	_	_
14-2	1817-1819	of	object[100]	new[100]	_	_
14-3	1820-1823	the	object[100]|object[101]	new[100]|giv[101]	_	_
14-4	1824-1835	manuscripts	object[100]|object[101]	new[100]|giv[101]	_	_
14-5	1836-1846	identified	_	_	_	_
14-6	1847-1849	in	_	_	_	_
14-7	1850-1853	the	abstract[103]	giv[103]	_	_
14-8	1854-1864	literature	abstract|abstract[103]	giv|giv[103]	_	_
14-9	1865-1871	search	abstract[103]	giv[103]	_	_
14-10	1872-1876	were	_	_	_	_
14-11	1877-1885	uploaded	_	_	_	_
14-12	1886-1890	into	_	_	_	_
14-13	1891-1892	a	abstract[104]	new[104]	_	_
14-14	1893-1902	web-based	abstract[104]	new[104]	_	_
14-15	1903-1909	system	abstract[104]	new[104]	_	_
14-16	1910-1911	,	_	_	_	_
14-17	1912-1917	which	_	_	_	_
14-18	1918-1921	was	_	_	_	_
14-19	1922-1926	used	_	_	_	_
14-20	1927-1929	to	_	_	_	_
14-21	1930-1936	manage	_	_	_	_
14-22	1937-1940	the	event[106]	new[106]	_	_
14-23	1941-1950	screening	abstract|event[106]	new|new[106]	_	_
14-24	1951-1958	process	event[106]	new[106]	_	_
14-25	1959-1962	and	_	_	_	_
14-26	1963-1969	remove	_	_	_	_
14-27	1970-1973	any	abstract[107]	new[107]	_	_
14-28	1974-1983	duplicate	abstract[107]	new[107]	_	_
14-29	1984-1993	citations	abstract[107]	new[107]	_	_
14-30	1994-1995	.	_	_	_	_

#Text=In order to determine which studies would be included , three members of the review team independently screened the titles and abstracts of these articles and the full texts were retrieved based on our inclusion and exclusion criteria .
15-1	1996-1998	In	_	_	_	_
15-2	1999-2004	order	_	_	_	_
15-3	2005-2007	to	_	_	_	_
15-4	2008-2017	determine	_	_	_	_
15-5	2018-2023	which	_	_	_	_
15-6	2024-2031	studies	event	giv	_	_
15-7	2032-2037	would	_	_	_	_
15-8	2038-2040	be	_	_	_	_
15-9	2041-2049	included	_	_	_	_
15-10	2050-2051	,	_	_	_	_
15-11	2052-2057	three	person[109]	new[109]	_	_
15-12	2058-2065	members	person[109]	new[109]	_	_
15-13	2066-2068	of	person[109]	new[109]	_	_
15-14	2069-2072	the	person[109]|organization[111]	new[109]|new[111]	_	_
15-15	2073-2079	review	person[109]|event|organization[111]	new[109]|new|new[111]	_	_
15-16	2080-2084	team	person[109]|organization[111]	new[109]|new[111]	_	_
15-17	2085-2098	independently	_	_	_	_
15-18	2099-2107	screened	_	_	_	_
15-19	2108-2111	the	abstract[112]	new[112]	_	_
15-20	2112-2118	titles	abstract[112]	new[112]	_	_
15-21	2119-2122	and	_	_	_	_
15-22	2123-2132	abstracts	abstract[113]	giv[113]	_	_
15-23	2133-2135	of	abstract[113]	giv[113]	_	_
15-24	2136-2141	these	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-25	2142-2150	articles	abstract[113]|abstract[114]	giv[113]|giv[114]	_	_
15-26	2151-2154	and	_	_	_	_
15-27	2155-2158	the	object[115]	new[115]	_	_
15-28	2159-2163	full	object[115]	new[115]	_	_
15-29	2164-2169	texts	object[115]	new[115]	_	_
15-30	2170-2174	were	_	_	_	_
15-31	2175-2184	retrieved	_	_	_	_
15-32	2185-2190	based	_	_	_	_
15-33	2191-2193	on	_	_	_	_
15-34	2194-2197	our	person|person[117]|abstract[118]	giv|giv[117]|giv[118]	coref|ana	16-33[0_117]|20-1
15-35	2198-2207	inclusion	person[117]|abstract[118]	giv[117]|giv[118]	_	_
15-36	2208-2211	and	abstract[118]	giv[118]	_	_
15-37	2212-2221	exclusion	abstract[118]|person|abstract[120]	giv[118]|new|giv[120]	_	_
15-38	2222-2230	criteria	abstract[118]|abstract[120]	giv[118]|giv[120]	_	_
15-39	2231-2232	.	_	_	_	_

#Text=Two reviewers independently extracted the following data from each article : The country in which the study was conducted , number of participants , age of the participants at the time of inclusion , sex of the participants , amount of leucine administered , co-administration of other substances , sarcopenia evaluation methods , and the main and secondary outcomes of the study .
16-1	2233-2236	Two	person[121]	new[121]	coref	17-4[142_121]
16-2	2237-2246	reviewers	person[121]	new[121]	_	_
16-3	2247-2260	independently	_	_	_	_
16-4	2261-2270	extracted	_	_	_	_
16-5	2271-2274	the	abstract[122]	new[122]	coref	17-10[0_122]
16-6	2275-2284	following	abstract[122]	new[122]	_	_
16-7	2285-2289	data	abstract[122]	new[122]	_	_
16-8	2290-2294	from	abstract[122]	new[122]	_	_
16-9	2295-2299	each	abstract[122]|object[123]	new[122]|new[123]	_	_
16-10	2300-2307	article	abstract[122]|object[123]	new[122]|new[123]	_	_
16-11	2308-2309	:	_	_	_	_
16-12	2310-2313	The	place[124]	new[124]	_	_
16-13	2314-2321	country	place[124]	new[124]	_	_
16-14	2322-2324	in	_	_	_	_
16-15	2325-2330	which	_	_	_	_
16-16	2331-2334	the	abstract[125]	giv[125]	coref	16-61[140_125]
16-17	2335-2340	study	abstract[125]	giv[125]	_	_
16-18	2341-2344	was	_	_	_	_
16-19	2345-2354	conducted	_	_	_	_
16-20	2355-2356	,	_	_	_	_
16-21	2357-2363	number	abstract[126]	new[126]	_	_
16-22	2364-2366	of	abstract[126]	new[126]	_	_
16-23	2367-2379	participants	abstract[126]|person	new[126]|new	coref	16-27[129_0]
16-24	2380-2381	,	_	_	_	_
16-25	2382-2385	age	abstract[128]	giv[128]	_	_
16-26	2386-2388	of	abstract[128]	giv[128]	_	_
16-27	2389-2392	the	abstract[128]|person[129]	giv[128]|giv[129]	coref	20-43[164_129]
16-28	2393-2405	participants	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-29	2406-2408	at	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-30	2409-2412	the	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-31	2413-2417	time	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-32	2418-2420	of	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-33	2421-2430	inclusion	abstract[128]|person[129]|person	giv[128]|giv[129]|giv	_	_
16-34	2431-2432	,	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-35	2433-2436	sex	abstract[128]|person[129]|abstract[131]	giv[128]|giv[129]|new[131]	_	_
16-36	2437-2439	of	abstract[128]|person[129]|abstract[131]	giv[128]|giv[129]|new[131]	_	_
16-37	2440-2443	the	abstract[128]|person[129]|abstract[131]	giv[128]|giv[129]|new[131]	_	_
16-38	2444-2456	participants	abstract[128]|person[129]|abstract[131]	giv[128]|giv[129]|new[131]	_	_
16-39	2457-2458	,	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-40	2459-2465	amount	abstract[128]|person[129]|quantity[132]	giv[128]|giv[129]|new[132]	_	_
16-41	2466-2468	of	abstract[128]|person[129]|quantity[132]	giv[128]|giv[129]|new[132]	_	_
16-42	2469-2476	leucine	abstract[128]|person[129]|quantity[132]|abstract	giv[128]|giv[129]|new[132]|giv	_	_
16-43	2477-2489	administered	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-44	2490-2491	,	abstract[128]|person[129]	giv[128]|giv[129]	_	_
16-45	2492-2509	co-administration	abstract[128]|person[129]|abstract[134]	giv[128]|giv[129]|new[134]	_	_
16-46	2510-2512	of	abstract[128]|person[129]|abstract[134]	giv[128]|giv[129]|new[134]	_	_
16-47	2513-2518	other	abstract[128]|person[129]|abstract[134]|substance[135]	giv[128]|giv[129]|new[134]|new[135]	_	_
16-48	2519-2529	substances	abstract[128]|person[129]|abstract[134]|substance[135]	giv[128]|giv[129]|new[134]|new[135]	_	_
16-49	2530-2531	,	abstract[128]|person[129]|abstract[134]	giv[128]|giv[129]|new[134]	_	_
16-50	2532-2542	sarcopenia	abstract[128]|person[129]|abstract[134]|abstract|abstract[138]	giv[128]|giv[129]|new[134]|giv|giv[138]	_	_
16-51	2543-2553	evaluation	abstract[128]|person[129]|abstract[134]|abstract|abstract[138]	giv[128]|giv[129]|new[134]|new|giv[138]	_	_
16-52	2554-2561	methods	abstract[128]|person[129]|abstract[134]|abstract[138]	giv[128]|giv[129]|new[134]|giv[138]	_	_
16-53	2562-2563	,	abstract[128]|person[129]|abstract[134]	giv[128]|giv[129]|new[134]	_	_
16-54	2564-2567	and	abstract[128]|person[129]|abstract[134]	giv[128]|giv[129]|new[134]	_	_
16-55	2568-2571	the	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-56	2572-2576	main	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-57	2577-2580	and	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-58	2581-2590	secondary	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-59	2591-2599	outcomes	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-60	2600-2602	of	abstract[128]|person[129]|abstract[134]|abstract[139]	giv[128]|giv[129]|new[134]|new[139]	_	_
16-61	2603-2606	the	abstract[128]|person[129]|abstract[134]|abstract[139]|abstract[140]	giv[128]|giv[129]|new[134]|new[139]|giv[140]	coref	20-8[153_140]
16-62	2607-2612	study	abstract[128]|person[129]|abstract[134]|abstract[139]|abstract[140]	giv[128]|giv[129]|new[134]|new[139]|giv[140]	_	_
16-63	2613-2614	.	_	_	_	_

#Text=Any disagreement between the reviewers regarding the papers and data extracted from them was resolved by the third author .
17-1	2615-2618	Any	abstract[141]	new[141]	_	_
17-2	2619-2631	disagreement	abstract[141]	new[141]	_	_
17-3	2632-2639	between	abstract[141]	new[141]	_	_
17-4	2640-2643	the	abstract[141]|person[142]	new[141]|giv[142]	_	_
17-5	2644-2653	reviewers	abstract[141]|person[142]	new[141]|giv[142]	_	_
17-6	2654-2663	regarding	_	_	_	_
17-7	2664-2667	the	abstract[143]	new[143]	_	_
17-8	2668-2674	papers	abstract[143]	new[143]	_	_
17-9	2675-2678	and	_	_	_	_
17-10	2679-2683	data	abstract	giv	ana	17-13
17-11	2684-2693	extracted	_	_	_	_
17-12	2694-2698	from	_	_	_	_
17-13	2699-2703	them	abstract	giv	_	_
17-14	2704-2707	was	_	_	_	_
17-15	2708-2716	resolved	_	_	_	_
17-16	2717-2719	by	_	_	_	_
17-17	2720-2723	the	person[146]	new[146]	coref	21-24[182_146]
17-18	2724-2729	third	person[146]	new[146]	_	_
17-19	2730-2736	author	person[146]	new[146]	_	_
17-20	2737-2738	.	_	_	_	_

#Text=2.4 .
18-1	2739-2742	2.4	abstract	new	_	_
18-2	2743-2744	.	_	_	_	_

#Text=Assessment of Bias
19-1	2745-2755	Assessment	abstract[148]	new[148]	coref	20-52[169_148]
19-2	2756-2758	of	abstract[148]	new[148]	_	_
19-3	2759-2763	Bias	abstract[148]|abstract	new[148]|new	coref	20-6[152_0]

#Text=We assessed the risk of bias in each randomised and placebo-controlled study according to the Cochrane Review guidelines , which cover the following bias domains : Selection bias ( random sequence generation and allocation concealment ) , performance bias ( blinding of participants and personnel ) , detection bias ( blinding the outcome assessment ) , attrition bias ( incomplete outcome data ) , and reporting bias ( selective reporting ) .
20-1	2764-2766	We	person	giv	_	_
20-2	2767-2775	assessed	_	_	_	_
20-3	2776-2779	the	abstract[151]	new[151]	_	_
20-4	2780-2784	risk	abstract[151]	new[151]	_	_
20-5	2785-2787	of	abstract[151]	new[151]	_	_
20-6	2788-2792	bias	abstract[151]|abstract[152]	new[151]|giv[152]	coref	20-24[0_152]
20-7	2793-2795	in	abstract[151]|abstract[152]	new[151]|giv[152]	_	_
20-8	2796-2800	each	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|giv[153]	_	_
20-9	2801-2811	randomised	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|giv[153]	_	_
20-10	2812-2815	and	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|giv[153]	_	_
20-11	2816-2834	placebo-controlled	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|giv[153]	_	_
20-12	2835-2840	study	abstract[151]|abstract[152]|abstract[153]	new[151]|giv[152]|giv[153]	_	_
20-13	2841-2850	according	_	_	_	_
20-14	2851-2853	to	_	_	_	_
20-15	2854-2857	the	abstract[156]	giv[156]	_	_
20-16	2858-2866	Cochrane	place|abstract[155]|abstract[156]	giv|new[155]|giv[156]	_	_
20-17	2867-2873	Review	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
20-18	2874-2884	guidelines	abstract[156]	giv[156]	_	_
20-19	2885-2886	,	_	_	_	_
20-20	2887-2892	which	_	_	_	_
20-21	2893-2898	cover	_	_	_	_
20-22	2899-2902	the	abstract[158]	new[158]	appos	20-27[160_158]
20-23	2903-2912	following	abstract[158]	new[158]	_	_
20-24	2913-2917	bias	abstract|abstract[158]	giv|new[158]	coref	20-48[167_0]
20-25	2918-2925	domains	abstract[158]	new[158]	_	_
20-26	2926-2927	:	_	_	_	_
20-27	2928-2937	Selection	abstract|abstract[160]	new|giv[160]	_	_
20-28	2938-2942	bias	abstract[160]	giv[160]	_	_
20-29	2943-2944	(	abstract[160]	giv[160]	_	_
20-30	2945-2951	random	abstract[160]	giv[160]	_	_
20-31	2952-2960	sequence	abstract[160]|abstract	giv[160]|new	_	_
20-32	2961-2971	generation	abstract[160]	giv[160]	_	_
20-33	2972-2975	and	abstract[160]	giv[160]	_	_
20-34	2976-2986	allocation	abstract[160]|abstract	giv[160]|new	_	_
20-35	2987-2998	concealment	abstract[160]	giv[160]	_	_
20-36	2999-3000	)	abstract[160]	giv[160]	_	_
20-37	3001-3002	,	abstract[160]	giv[160]	_	_
20-38	3003-3014	performance	abstract[160]|abstract	giv[160]|giv	_	_
20-39	3015-3019	bias	abstract[160]	giv[160]	_	_
20-40	3020-3021	(	abstract[160]	giv[160]	_	_
20-41	3022-3030	blinding	abstract[160]	giv[160]	_	_
20-42	3031-3033	of	_	_	_	_
20-43	3034-3046	participants	person[164]	giv[164]	_	_
20-44	3047-3050	and	person[164]	giv[164]	_	_
20-45	3051-3060	personnel	person[164]|person	giv[164]|new	_	_
20-46	3061-3062	)	_	_	_	_
20-47	3063-3064	,	_	_	_	_
20-48	3065-3074	detection	abstract|abstract[167]	new|giv[167]	coref	20-57[171_167]
20-49	3075-3079	bias	abstract[167]	giv[167]	_	_
20-50	3080-3081	(	_	_	_	_
20-51	3082-3090	blinding	_	_	_	_
20-52	3091-3094	the	abstract[169]	giv[169]	_	_
20-53	3095-3102	outcome	abstract|abstract[169]	new|giv[169]	coref	20-61
20-54	3103-3113	assessment	abstract[169]	giv[169]	_	_
20-55	3114-3115	)	_	_	_	_
20-56	3116-3117	,	_	_	_	_
20-57	3118-3127	attrition	event|abstract[171]	new|giv[171]	appos	20-60[173_171]
20-58	3128-3132	bias	abstract[171]	giv[171]	_	_
20-59	3133-3134	(	_	_	_	_
20-60	3135-3145	incomplete	abstract[173]	giv[173]	coref	20-66[174_173]
20-61	3146-3153	outcome	abstract|abstract[173]	giv|giv[173]	_	_
20-62	3154-3158	data	abstract[173]	giv[173]	_	_
20-63	3159-3160	)	_	_	_	_
20-64	3161-3162	,	_	_	_	_
20-65	3163-3166	and	_	_	_	_
20-66	3167-3176	reporting	abstract[174]	giv[174]	appos	20-69[175_174]
20-67	3177-3181	bias	abstract[174]	giv[174]	_	_
20-68	3182-3183	(	_	_	_	_
20-69	3184-3193	selective	abstract[175]	giv[175]	_	_
20-70	3194-3203	reporting	abstract[175]	giv[175]	_	_
20-71	3204-3205	)	_	_	_	_
20-72	3206-3207	.	_	_	_	_

#Text=The judgments were made independently by two researchers ( FM - M – A and R-F-V ) , with any discrepancies resolved with the third author ( OC ) .
21-1	3208-3211	The	abstract[176]	new[176]	_	_
21-2	3212-3221	judgments	abstract[176]	new[176]	_	_
21-3	3222-3226	were	_	_	_	_
21-4	3227-3231	made	_	_	_	_
21-5	3232-3245	independently	_	_	_	_
21-6	3246-3248	by	_	_	_	_
21-7	3249-3252	two	person[177]	new[177]	appos	21-10[178_177]
21-8	3253-3264	researchers	person[177]	new[177]	_	_
21-9	3265-3266	(	_	_	_	_
21-10	3267-3269	FM	person[178]	giv[178]	_	_
21-11	3270-3271	-	person[178]	giv[178]	_	_
21-12	3272-3273	M	person[178]|abstract	giv[178]|new	_	_
21-13	3274-3275	–	person[178]	giv[178]	_	_
21-14	3276-3277	A	person[178]|person[180]	giv[178]|new[180]	_	_
21-15	3278-3281	and	person[178]|person[180]	giv[178]|new[180]	_	_
21-16	3282-3287	R-F-V	person[178]|person[180]	giv[178]|new[180]	_	_
21-17	3288-3289	)	_	_	_	_
21-18	3290-3291	,	_	_	_	_
21-19	3292-3296	with	_	_	_	_
21-20	3297-3300	any	abstract[181]	new[181]	_	_
21-21	3301-3314	discrepancies	abstract[181]	new[181]	_	_
21-22	3315-3323	resolved	_	_	_	_
21-23	3324-3328	with	_	_	_	_
21-24	3329-3332	the	person[182]	giv[182]	appos	21-28[0_182]
21-25	3333-3338	third	person[182]	giv[182]	_	_
21-26	3339-3345	author	person[182]	giv[182]	_	_
21-27	3346-3347	(	_	_	_	_
21-28	3348-3350	OC	person	giv	_	_
21-29	3351-3352	)	_	_	_	_
21-30	3353-3354	.	_	_	_	_
